Suppr超能文献

内皮祖细胞疗法在颅内动脉瘤治疗中的机制及应用

The mechanisms and applications of endothelial progenitor cell therapy in the treatment of intracranial aneurysm.

作者信息

Shen Shiyu, Pan Tonglin, Liu Peixi, Tian Yanlong, Shi Yuan, Zhu Wei

机构信息

Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.

National Center for Neurological Disorders, Shanghai, China.

出版信息

J Transl Med. 2025 Mar 27;23(1):377. doi: 10.1186/s12967-025-06401-w.

Abstract

The pathophysiological mechanism of intracranial aneurysm (IA) involves the dynamic interaction of ECM abnormalities, hemodynamic stress, and inflammatory response. The rupture of intracranial aneurysm will cause serious consequences. Multiple studies have confirmed the important role and potential application of endothelial progenitor cells (EPCs) in vascular repair. This review focuses on the specific mechanism of EPCs in the treatment of intracranial aneurysms, which promote re-endothelialization and angiogenesis through bone marrow mobilization, targeted migration to the site of injury, differentiation into mature endothelial cells, and secretion of angiogenic factors. In addition, EPCs maintain ECM homeostasis by regulating MMP/IMP balance, inhibiting aneurysm wall thinning and structural damage. Based on the vascular repair mechanism of EPCs, new treatment strategies such as "biologically active" spring coils (loaded with EPCs or SDF-1α) and flow diverters(FDs) combined with EPCs therapy have been developed to synergistically promote carotid endothelialization of aneurysms and reduce the risk of recurrence. Future research needs to further validate the long-term efficacy and precise regulatory mechanisms of EPCs in clinical translation, providing new directions for IA treatment.

摘要

颅内动脉瘤(IA)的病理生理机制涉及细胞外基质(ECM)异常、血流动力学应激和炎症反应之间的动态相互作用。颅内动脉瘤破裂会导致严重后果。多项研究证实了内皮祖细胞(EPCs)在血管修复中的重要作用及潜在应用。本综述聚焦于EPCs治疗颅内动脉瘤的具体机制,其通过骨髓动员、靶向迁移至损伤部位、分化为成熟内皮细胞以及分泌血管生成因子来促进再内皮化和血管生成。此外,EPCs通过调节基质金属蛋白酶(MMP)/金属蛋白酶组织抑制剂(IMP)平衡来维持ECM稳态,抑制动脉瘤壁变薄和结构损伤。基于EPCs的血管修复机制,已开发出“生物活性”弹簧圈(负载EPCs或基质细胞衍生因子-1α[SDF-1α])和血流导向装置(FDs)联合EPCs治疗等新的治疗策略,以协同促进动脉瘤的颈动脉内皮化并降低复发风险。未来的研究需要在临床转化中进一步验证EPCs的长期疗效和精确调控机制,为IA治疗提供新方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f719/11951544/1da3bc50063a/12967_2025_6401_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验